We looked at 215 patients treated with IP ICIs from 2012-2021. Three-quarters had advanced solid cancers and the same proportion were ICI naive. Median OS from the first dose of IP ICI was 1.55 mo, and among pts with adv solid tumors, 1.28 mo. 25% died in the hospital.

Many institutions disallow or limit ICIs for hospitalized pts w/cancer because they have to eat the cost. But what about clinical benefits? Our group examined clinical outcomes of pts treated with inpatient ICIs at 5 large academic institutions. ascopubs.org/doi/10.1200/...